In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more. Read the full coverage here: Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC Global economic cost of cancer estimated to exceed $25 trillion over 30 years Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints Researchers develop AI model to accelerate radiation therapy planning for lung cancer Asian, Black patients with lung cancer face longer wait times to radiation treatment References: Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826. Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7. Press Release Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104 Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.

Ver todos los episodios